SlideShare uma empresa Scribd logo
1 de 47
HTN new Updates Dr Ihab Suliman MBBS,ECFMG(USA),DCBNC(USA), MRCP(UK) Associate Consultant Cardiology Member of the European Working Group on Nuclear Cardiology & Cardiac CT
Case  ,[object Object]
[object Object],[object Object],[object Object]
[object Object]
HTN Defined ,[object Object],[object Object],[object Object],[object Object],[object Object],[object Object]
Properly Measured ,[object Object],[object Object],[object Object],[object Object]
Hypertension Risk Factors ,[object Object],[object Object],[object Object],[object Object],[object Object]
Benefits of HTN Rx ,[object Object],[object Object],[object Object]
NNT ,[object Object]
Case  ,[object Object],[object Object],[object Object],[object Object],[object Object]
[object Object],[object Object],[object Object],[object Object],[object Object],[object Object],[object Object],[object Object]
[object Object],[object Object],[object Object],[object Object],[object Object]
[object Object]
[object Object]
[object Object],[object Object],[object Object],[object Object],[object Object]
Hypertensive Urgency & Emergency ,[object Object],[object Object],[object Object],[object Object]
[object Object],[object Object]
Hypertensive Emergency Sx ,[object Object],[object Object],[object Object],[object Object]
[object Object],[object Object],[object Object]
[object Object],[object Object],[object Object]
Algorithm for Treatment of Hypertension  (JNC 7)  JAMA, May 2003 Not at Goal Blood Pressure (<140/90 mmHg)  (<130/80 mmHg for those with diabetes or chronic kidney disease) Initial Drug Choices Lifestyle Modifications Drug(s) for the compelling indications  With Compelling  Indications Stage 2 Hypertension   2-drug combination for most  Stage 1 Hypertension   Thiazide-type diuretics for most.  May consider ACEI, ARB, BB, CCB, or combination Without Compelling  Indications
Case  ,[object Object],[object Object],[object Object],[object Object]
[object Object],[object Object],[object Object],[object Object],[object Object]
[object Object]
Choosing drugs for patients newly diagnosed with hypertension BHS Guidelines (June 2006) Younger than 55 years 55 years or older Or black patients  of any age A C or D A+C or A+D A+C+D ,[object Object],[object Object],[object Object],[object Object],[object Object],Abbreviations: A: ACE-I (or ARB if ACE intolerant) C: CCB D: thiazide type diuretic Step 1 Step 2 Step 3 Step 4
Hypertension and Diabetes Recommendations of the American Diabetic Association  ,[object Object],[object Object],[object Object],American Diabetes Association. Diabetes Care.  2005; 28 (Suppl 1): S10 – S17.
Conditions favoring the use of ARBs ,[object Object],[object Object],[object Object],[object Object],[object Object]
Case 1 ,[object Object],[object Object]
[object Object],[object Object],[object Object],[object Object],[object Object]
[object Object]
[object Object],[object Object],[object Object],[object Object],[object Object]
[object Object]
The following are Positive trials? ,[object Object],[object Object],[object Object]
The following are Positive trials? ,[object Object]
Prevalence of HTN ,[object Object],[object Object],[object Object],[object Object]
[object Object]
Case  ,[object Object],[object Object],[object Object],[object Object]
[object Object]
Scientific evidence ,[object Object],[object Object],[object Object],[object Object]
[object Object]
ALLHAT study ,[object Object],[object Object],[object Object],[object Object]
[object Object]
HERs The Heart & estrogen Replacement therapy study ,[object Object],[object Object],[object Object],[object Object],[object Object]
[object Object],[object Object],[object Object],[object Object]
Development of new diabetes – CHARM study 0 10 20 30 40 50 60 70 80 No. of  cases  developing  new  Diabetes Control candesartan 40% p =0.005 Lancet, 2003
© 2008, American Heart Association. All rights reserved.  ,[object Object],[object Object],Resistant Hypertension
[object Object]

Mais conteúdo relacionado

Mais procurados

Case on heart failure (hypertrophic cardiomyopathy)
Case on heart failure (hypertrophic cardiomyopathy)Case on heart failure (hypertrophic cardiomyopathy)
Case on heart failure (hypertrophic cardiomyopathy)
Dr. Abhimanyu Prashar
 
Treatment Of Hypertension In Special Situation Modified Fina Lc
Treatment Of Hypertension In Special Situation Modified Fina LcTreatment Of Hypertension In Special Situation Modified Fina Lc
Treatment Of Hypertension In Special Situation Modified Fina Lc
drmisbah83
 
2017 blood-pressure-guideline
2017 blood-pressure-guideline2017 blood-pressure-guideline
2017 blood-pressure-guideline
PHAM HUU THAI
 
Recent Developments in the Treatment of Hypertension Recent Developments in...
Recent Developments in the Treatment of Hypertension 	 Recent Developments in...Recent Developments in the Treatment of Hypertension 	 Recent Developments in...
Recent Developments in the Treatment of Hypertension Recent Developments in...
MedicineAndFamily
 
1.6.2 Pharmacologic Treatment
1.6.2 Pharmacologic Treatment1.6.2 Pharmacologic Treatment
1.6.2 Pharmacologic Treatment
medicinaudm
 

Mais procurados (20)

Royal control in hypertension
Royal control in hypertension   Royal control in hypertension
Royal control in hypertension
 
Case on heart failure (hypertrophic cardiomyopathy)
Case on heart failure (hypertrophic cardiomyopathy)Case on heart failure (hypertrophic cardiomyopathy)
Case on heart failure (hypertrophic cardiomyopathy)
 
A case study on anemia with congestive heart failure
A case study on anemia with congestive heart failureA case study on anemia with congestive heart failure
A case study on anemia with congestive heart failure
 
2 cases of chest pain
2 cases of chest pain2 cases of chest pain
2 cases of chest pain
 
Treatment Of Hypertension In Special Situation Modified Fina Lc
Treatment Of Hypertension In Special Situation Modified Fina LcTreatment Of Hypertension In Special Situation Modified Fina Lc
Treatment Of Hypertension In Special Situation Modified Fina Lc
 
2017 blood-pressure-guideline
2017 blood-pressure-guideline2017 blood-pressure-guideline
2017 blood-pressure-guideline
 
Hypertension; Basics- Recommendations - Special Situations
Hypertension; Basics-  Recommendations - Special SituationsHypertension; Basics-  Recommendations - Special Situations
Hypertension; Basics- Recommendations - Special Situations
 
2017 high blood pressure clinical practice guideline
2017 high blood pressure clinical practice guideline2017 high blood pressure clinical practice guideline
2017 high blood pressure clinical practice guideline
 
Recent Developments in the Treatment of Hypertension Recent Developments in...
Recent Developments in the Treatment of Hypertension 	 Recent Developments in...Recent Developments in the Treatment of Hypertension 	 Recent Developments in...
Recent Developments in the Treatment of Hypertension Recent Developments in...
 
PARKINSON CASE FINAL
PARKINSON CASE FINALPARKINSON CASE FINAL
PARKINSON CASE FINAL
 
1.6.2 Pharmacologic Treatment
1.6.2 Pharmacologic Treatment1.6.2 Pharmacologic Treatment
1.6.2 Pharmacologic Treatment
 
SOAPping MI
SOAPping MISOAPping MI
SOAPping MI
 
2017 hypertension guidelines
2017 hypertension guidelines 2017 hypertension guidelines
2017 hypertension guidelines
 
Case presentation on Acute Ischemic stroke
Case presentation on Acute Ischemic strokeCase presentation on Acute Ischemic stroke
Case presentation on Acute Ischemic stroke
 
Lec 7 hypertension for mohs
Lec 7  hypertension for mohsLec 7  hypertension for mohs
Lec 7 hypertension for mohs
 
A Case study on OSTEOARTHRITIS by NOM
A Case study on OSTEOARTHRITIS by NOM  A Case study on OSTEOARTHRITIS by NOM
A Case study on OSTEOARTHRITIS by NOM
 
Hypertension
HypertensionHypertension
Hypertension
 
Hypertension guidelines
Hypertension guidelinesHypertension guidelines
Hypertension guidelines
 
Case Presentation on STROKE (Subarachnoid Hemorrhage)
Case Presentation on STROKE (Subarachnoid Hemorrhage)Case Presentation on STROKE (Subarachnoid Hemorrhage)
Case Presentation on STROKE (Subarachnoid Hemorrhage)
 
The 2017 Hypertension Guideline Update and the Need for Revised Clinical Content
The 2017 Hypertension Guideline Update and the Need for Revised Clinical ContentThe 2017 Hypertension Guideline Update and the Need for Revised Clinical Content
The 2017 Hypertension Guideline Update and the Need for Revised Clinical Content
 

Destaque

Diagnostic evaluation of HTN
Diagnostic evaluation of HTNDiagnostic evaluation of HTN
Diagnostic evaluation of HTN
Hany Ahmad
 
Triple terapia anti hta junio 2010
Triple terapia anti hta junio 2010Triple terapia anti hta junio 2010
Triple terapia anti hta junio 2010
Dario Adames
 
Blood pressure control in diabetes
Blood pressure control in diabetesBlood pressure control in diabetes
Blood pressure control in diabetes
BALASUBRAMANIAM IYER
 
Co valtin
Co valtinCo valtin
Co valtin
mrahamn
 
Hypertension- Update on current guideline 02.18.16
Hypertension- Update on current guideline 02.18.16Hypertension- Update on current guideline 02.18.16
Hypertension- Update on current guideline 02.18.16
Thu Nguyen
 
Prof .Aziz-ur-Rehman
Prof .Aziz-ur-RehmanProf .Aziz-ur-Rehman
Prof .Aziz-ur-Rehman
Pk Doctors
 

Destaque (15)

Hypertension the silent killer
Hypertension the silent killer Hypertension the silent killer
Hypertension the silent killer
 
Diagnostic evaluation of HTN
Diagnostic evaluation of HTNDiagnostic evaluation of HTN
Diagnostic evaluation of HTN
 
Triple terapia anti hta junio 2010
Triple terapia anti hta junio 2010Triple terapia anti hta junio 2010
Triple terapia anti hta junio 2010
 
ueda2011 hypertensive diabetic patient-d.adel
ueda2011 hypertensive diabetic patient-d.adelueda2011 hypertensive diabetic patient-d.adel
ueda2011 hypertensive diabetic patient-d.adel
 
Blood pressure control in diabetes
Blood pressure control in diabetesBlood pressure control in diabetes
Blood pressure control in diabetes
 
JNC-8 Blood Pressure and ACC/AHA Cholesterol Guideline Updates
JNC-8 Blood Pressure and ACC/AHA Cholesterol Guideline UpdatesJNC-8 Blood Pressure and ACC/AHA Cholesterol Guideline Updates
JNC-8 Blood Pressure and ACC/AHA Cholesterol Guideline Updates
 
Management Of Hypertension in diabetes- 2009
Management Of Hypertension in diabetes- 2009Management Of Hypertension in diabetes- 2009
Management Of Hypertension in diabetes- 2009
 
Orbapin 5 20
Orbapin 5 20Orbapin 5 20
Orbapin 5 20
 
Co valtin
Co valtinCo valtin
Co valtin
 
CCB-ARB combination is better than mono-therapyPresentation seminar 2-cmosmch
CCB-ARB combination is better than mono-therapyPresentation  seminar 2-cmosmchCCB-ARB combination is better than mono-therapyPresentation  seminar 2-cmosmch
CCB-ARB combination is better than mono-therapyPresentation seminar 2-cmosmch
 
Hypertension- Update on current guideline 02.18.16
Hypertension- Update on current guideline 02.18.16Hypertension- Update on current guideline 02.18.16
Hypertension- Update on current guideline 02.18.16
 
The Hypertension Guidelines JNC 8
The Hypertension Guidelines JNC 8 The Hypertension Guidelines JNC 8
The Hypertension Guidelines JNC 8
 
Jnc 8
Jnc 8Jnc 8
Jnc 8
 
JNC 8 _Dr. Mansij Biswas
JNC 8 _Dr. Mansij BiswasJNC 8 _Dr. Mansij Biswas
JNC 8 _Dr. Mansij Biswas
 
Prof .Aziz-ur-Rehman
Prof .Aziz-ur-RehmanProf .Aziz-ur-Rehman
Prof .Aziz-ur-Rehman
 

Semelhante a Ht Nlecture2009

Session 2 Hypertension | Dr. Ahmed othman
Session 2 Hypertension | Dr. Ahmed othmanSession 2 Hypertension | Dr. Ahmed othman
Session 2 Hypertension | Dr. Ahmed othman
Emad Qasem
 
Treatment of Hypertension Treatment of Hypertension
Treatment of Hypertension 	 Treatment of HypertensionTreatment of Hypertension 	 Treatment of Hypertension
Treatment of Hypertension Treatment of Hypertension
MedicineAndHealthCancer
 
Dt benh THA và chien luoc phoi hop thuoc nham dat muc tieu dt - Cn cac khuye...
Dt benh THA và chien luoc phoi hop thuoc nham dat muc tieu dt - Cn cac khuye...Dt benh THA và chien luoc phoi hop thuoc nham dat muc tieu dt - Cn cac khuye...
Dt benh THA và chien luoc phoi hop thuoc nham dat muc tieu dt - Cn cac khuye...
thito6
 

Semelhante a Ht Nlecture2009 (20)

Session 2 Hypertension | Dr. Ahmed othman
Session 2 Hypertension | Dr. Ahmed othmanSession 2 Hypertension | Dr. Ahmed othman
Session 2 Hypertension | Dr. Ahmed othman
 
PHARMACOTHERAPY POINTERS FOR HTN (MALAYSIAN CPGs).pdf
PHARMACOTHERAPY POINTERS FOR HTN (MALAYSIAN CPGs).pdfPHARMACOTHERAPY POINTERS FOR HTN (MALAYSIAN CPGs).pdf
PHARMACOTHERAPY POINTERS FOR HTN (MALAYSIAN CPGs).pdf
 
Hypertension
HypertensionHypertension
Hypertension
 
Caso clínico hasaaaaaaaaaaaaaaaaaaaaaaaaa
Caso clínico hasaaaaaaaaaaaaaaaaaaaaaaaaaCaso clínico hasaaaaaaaaaaaaaaaaaaaaaaaaa
Caso clínico hasaaaaaaaaaaaaaaaaaaaaaaaaa
 
Treatment of Hypertension Treatment of Hypertension
Treatment of Hypertension 	 Treatment of HypertensionTreatment of Hypertension 	 Treatment of Hypertension
Treatment of Hypertension Treatment of Hypertension
 
Management of hypertension problems in gp
Management of hypertension problems in gpManagement of hypertension problems in gp
Management of hypertension problems in gp
 
Dt benh THA và chien luoc phoi hop thuoc nham dat muc tieu dt - Cn cac khuye...
Dt benh THA và chien luoc phoi hop thuoc nham dat muc tieu dt - Cn cac khuye...Dt benh THA và chien luoc phoi hop thuoc nham dat muc tieu dt - Cn cac khuye...
Dt benh THA và chien luoc phoi hop thuoc nham dat muc tieu dt - Cn cac khuye...
 
Dieu tri-benh-tang-huyet-ap-va-chien-luoc-phoi-hop-thuoc-nham-dat-muc-tieu-di...
Dieu tri-benh-tang-huyet-ap-va-chien-luoc-phoi-hop-thuoc-nham-dat-muc-tieu-di...Dieu tri-benh-tang-huyet-ap-va-chien-luoc-phoi-hop-thuoc-nham-dat-muc-tieu-di...
Dieu tri-benh-tang-huyet-ap-va-chien-luoc-phoi-hop-thuoc-nham-dat-muc-tieu-di...
 
HYPERTENSION -THE LATEST MANAGEMENT
HYPERTENSION -THE LATEST MANAGEMENTHYPERTENSION -THE LATEST MANAGEMENT
HYPERTENSION -THE LATEST MANAGEMENT
 
Bugando Hypertension.pptx
Bugando Hypertension.pptxBugando Hypertension.pptx
Bugando Hypertension.pptx
 
Hypertension Guidelines JNC 8
Hypertension Guidelines JNC 8Hypertension Guidelines JNC 8
Hypertension Guidelines JNC 8
 
Debate evidence bases guideline handler
Debate evidence bases guideline handlerDebate evidence bases guideline handler
Debate evidence bases guideline handler
 
Hypertension jnc 8 guideline(1)
Hypertension jnc 8 guideline(1)Hypertension jnc 8 guideline(1)
Hypertension jnc 8 guideline(1)
 
Hypertension
HypertensionHypertension
Hypertension
 
HYPERTENSION.pptx
HYPERTENSION.pptxHYPERTENSION.pptx
HYPERTENSION.pptx
 
Pediatrics hypertension
Pediatrics hypertensionPediatrics hypertension
Pediatrics hypertension
 
JNC 8 REVIEW AND SOME CASES OF SECONDARY HYPERTENSION
JNC 8 REVIEW AND SOME CASES OF SECONDARY HYPERTENSIONJNC 8 REVIEW AND SOME CASES OF SECONDARY HYPERTENSION
JNC 8 REVIEW AND SOME CASES OF SECONDARY HYPERTENSION
 
Hypertension latest guidelines seminar(2017 ACC/AHA guidelines)
Hypertension latest guidelines seminar(2017 ACC/AHA guidelines)Hypertension latest guidelines seminar(2017 ACC/AHA guidelines)
Hypertension latest guidelines seminar(2017 ACC/AHA guidelines)
 
Treatment of Hypertension YAKES.ppt
Treatment of Hypertension YAKES.pptTreatment of Hypertension YAKES.ppt
Treatment of Hypertension YAKES.ppt
 
JNC-8.ppt
JNC-8.pptJNC-8.ppt
JNC-8.ppt
 

Mais de hospital

Reading and interpreting Holter2023.pptx
Reading and interpreting Holter2023.pptxReading and interpreting Holter2023.pptx
Reading and interpreting Holter2023.pptx
hospital
 
Learning case of strongly positive PET-CT Rubidium 82 on all parameters.ppt
Learning case of strongly positive PET-CT Rubidium 82 on all parameters.pptLearning case of strongly positive PET-CT Rubidium 82 on all parameters.ppt
Learning case of strongly positive PET-CT Rubidium 82 on all parameters.ppt
hospital
 
The Role of PET-CT imaging in the diagnosis of cardiac sarcoidosis post cardi...
The Role of PET-CT imaging in the diagnosis of cardiac sarcoidosis post cardi...The Role of PET-CT imaging in the diagnosis of cardiac sarcoidosis post cardi...
The Role of PET-CT imaging in the diagnosis of cardiac sarcoidosis post cardi...
hospital
 

Mais de hospital (20)

Nuclear cases Saturday 2023.pptx
Nuclear cases Saturday 2023.pptxNuclear cases Saturday 2023.pptx
Nuclear cases Saturday 2023.pptx
 
2023 HF p EF.pptx
2023 HF p EF.pptx2023 HF p EF.pptx
2023 HF p EF.pptx
 
SURGICAL MANGEMNT of VHD 2023fffffffff.pptx
SURGICAL MANGEMNT of VHD 2023fffffffff.pptxSURGICAL MANGEMNT of VHD 2023fffffffff.pptx
SURGICAL MANGEMNT of VHD 2023fffffffff.pptx
 
Reading and interpreting Holter2023.pptx
Reading and interpreting Holter2023.pptxReading and interpreting Holter2023.pptx
Reading and interpreting Holter2023.pptx
 
Complications_of_Diabetes.ppt
Complications_of_Diabetes.pptComplications_of_Diabetes.ppt
Complications_of_Diabetes.ppt
 
SURGICAL MANGEMNT of VHD 2023.pptx
SURGICAL MANGEMNT of VHD 2023.pptxSURGICAL MANGEMNT of VHD 2023.pptx
SURGICAL MANGEMNT of VHD 2023.pptx
 
the worst Medical Errors and how to mange them.pptx
the worst  Medical Errors and how to mange them.pptxthe worst  Medical Errors and how to mange them.pptx
the worst Medical Errors and how to mange them.pptx
 
Radionuclide Imaging of Cardiac Amyloidosis and SarcoidosisFELLOWS LECTUREupd...
Radionuclide Imaging of Cardiac Amyloidosis and SarcoidosisFELLOWS LECTUREupd...Radionuclide Imaging of Cardiac Amyloidosis and SarcoidosisFELLOWS LECTUREupd...
Radionuclide Imaging of Cardiac Amyloidosis and SarcoidosisFELLOWS LECTUREupd...
 
End Organ Damage In HypertensionDARB.pptx
End Organ Damage In HypertensionDARB.pptxEnd Organ Damage In HypertensionDARB.pptx
End Organ Damage In HypertensionDARB.pptx
 
DELIVER delivered 2022.pptx
DELIVER delivered 2022.pptxDELIVER delivered 2022.pptx
DELIVER delivered 2022.pptx
 
Percutaneous Revascularization for Ischemic Left Ventricular Dysfunction REV...
Percutaneous Revascularization for Ischemic Left Ventricular Dysfunction  REV...Percutaneous Revascularization for Ischemic Left Ventricular Dysfunction  REV...
Percutaneous Revascularization for Ischemic Left Ventricular Dysfunction REV...
 
Acetazolamide in Acute Decompensated Heart Failure with Volume ADVOR.pptx
Acetazolamide in Acute Decompensated Heart Failure with Volume ADVOR.pptxAcetazolamide in Acute Decompensated Heart Failure with Volume ADVOR.pptx
Acetazolamide in Acute Decompensated Heart Failure with Volume ADVOR.pptx
 
MRCP SUDAN QUESTIONS.pptx
MRCP SUDAN QUESTIONS.pptxMRCP SUDAN QUESTIONS.pptx
MRCP SUDAN QUESTIONS.pptx
 
DM LECTURE PROJECT.pptx
DM LECTURE  PROJECT.pptxDM LECTURE  PROJECT.pptx
DM LECTURE PROJECT.pptx
 
Learning case of strongly positive PET-CT Rubidium 82 on all parameters.ppt
Learning case of strongly positive PET-CT Rubidium 82 on all parameters.pptLearning case of strongly positive PET-CT Rubidium 82 on all parameters.ppt
Learning case of strongly positive PET-CT Rubidium 82 on all parameters.ppt
 
The Role of PET-CT imaging in the diagnosis of cardiac sarcoidosis post cardi...
The Role of PET-CT imaging in the diagnosis of cardiac sarcoidosis post cardi...The Role of PET-CT imaging in the diagnosis of cardiac sarcoidosis post cardi...
The Role of PET-CT imaging in the diagnosis of cardiac sarcoidosis post cardi...
 
Diabetes mellitus and vascular disease 2022 FINALD.pptx
Diabetes mellitus and vascular disease 2022 FINALD.pptxDiabetes mellitus and vascular disease 2022 FINALD.pptx
Diabetes mellitus and vascular disease 2022 FINALD.pptx
 
Nuc part BBBB.pptx
Nuc part BBBB.pptxNuc part BBBB.pptx
Nuc part BBBB.pptx
 
Non Invasive testing of myocardial ischemia AA.pptx
Non Invasive testing of myocardial ischemia AA.pptxNon Invasive testing of myocardial ischemia AA.pptx
Non Invasive testing of myocardial ischemia AA.pptx
 
Inherited aortopathy2022
Inherited aortopathy2022Inherited aortopathy2022
Inherited aortopathy2022
 

Último

Unit 4 Pharmaceutical Organic Chemisty 3 Quinoline
Unit 4 Pharmaceutical Organic Chemisty 3 QuinolineUnit 4 Pharmaceutical Organic Chemisty 3 Quinoline
Unit 4 Pharmaceutical Organic Chemisty 3 Quinoline
AarishRathnam1
 
Cytoskeleton and Cell Inclusions - Dr Muhammad Ali Rabbani - Medicose Academics
Cytoskeleton and Cell Inclusions - Dr Muhammad Ali Rabbani - Medicose AcademicsCytoskeleton and Cell Inclusions - Dr Muhammad Ali Rabbani - Medicose Academics
Cytoskeleton and Cell Inclusions - Dr Muhammad Ali Rabbani - Medicose Academics
MedicoseAcademics
 

Último (20)

Unit 4 Pharmaceutical Organic Chemisty 3 Quinoline
Unit 4 Pharmaceutical Organic Chemisty 3 QuinolineUnit 4 Pharmaceutical Organic Chemisty 3 Quinoline
Unit 4 Pharmaceutical Organic Chemisty 3 Quinoline
 
duus neurology.pdf anatomy. phisiology///
duus neurology.pdf anatomy. phisiology///duus neurology.pdf anatomy. phisiology///
duus neurology.pdf anatomy. phisiology///
 
The Clean Living Project Episode 24 - Subconscious
The Clean Living Project Episode 24 - SubconsciousThe Clean Living Project Episode 24 - Subconscious
The Clean Living Project Episode 24 - Subconscious
 
Storage of Blood Components- equipments, effects of improper storage, transpo...
Storage of Blood Components- equipments, effects of improper storage, transpo...Storage of Blood Components- equipments, effects of improper storage, transpo...
Storage of Blood Components- equipments, effects of improper storage, transpo...
 
Drug development life cycle indepth overview.pptx
Drug development life cycle indepth overview.pptxDrug development life cycle indepth overview.pptx
Drug development life cycle indepth overview.pptx
 
SEMESTER-V CHILD HEALTH NURSING-UNIT-1-INTRODUCTION.pdf
SEMESTER-V CHILD HEALTH NURSING-UNIT-1-INTRODUCTION.pdfSEMESTER-V CHILD HEALTH NURSING-UNIT-1-INTRODUCTION.pdf
SEMESTER-V CHILD HEALTH NURSING-UNIT-1-INTRODUCTION.pdf
 
Gallbladder Double-Diverticular: A Case Report المرارة مزدوجة التج: تقرير حالة
Gallbladder Double-Diverticular: A Case Report  المرارة مزدوجة التج: تقرير حالةGallbladder Double-Diverticular: A Case Report  المرارة مزدوجة التج: تقرير حالة
Gallbladder Double-Diverticular: A Case Report المرارة مزدوجة التج: تقرير حالة
 
Overview on the Automatic pill identifier
Overview on the Automatic pill identifierOverview on the Automatic pill identifier
Overview on the Automatic pill identifier
 
CONGENITAL HYPERTROPHIC PYLORIC STENOSIS by Dr M.KARTHIK EMMANUEL
CONGENITAL HYPERTROPHIC PYLORIC STENOSIS  by Dr M.KARTHIK EMMANUELCONGENITAL HYPERTROPHIC PYLORIC STENOSIS  by Dr M.KARTHIK EMMANUEL
CONGENITAL HYPERTROPHIC PYLORIC STENOSIS by Dr M.KARTHIK EMMANUEL
 
Bangalore whatsapp Number Just VIP Brookefield 100% Genuine at your Door Step
Bangalore whatsapp Number Just VIP Brookefield 100% Genuine at your Door StepBangalore whatsapp Number Just VIP Brookefield 100% Genuine at your Door Step
Bangalore whatsapp Number Just VIP Brookefield 100% Genuine at your Door Step
 
Cytoskeleton and Cell Inclusions - Dr Muhammad Ali Rabbani - Medicose Academics
Cytoskeleton and Cell Inclusions - Dr Muhammad Ali Rabbani - Medicose AcademicsCytoskeleton and Cell Inclusions - Dr Muhammad Ali Rabbani - Medicose Academics
Cytoskeleton and Cell Inclusions - Dr Muhammad Ali Rabbani - Medicose Academics
 
Top 10 Most Beautiful Russian Pornstars List 2024
Top 10 Most Beautiful Russian Pornstars List 2024Top 10 Most Beautiful Russian Pornstars List 2024
Top 10 Most Beautiful Russian Pornstars List 2024
 
Histopathological staining techniques used in liver diseases
Histopathological staining techniques used in liver diseasesHistopathological staining techniques used in liver diseases
Histopathological staining techniques used in liver diseases
 
Negative Pressure Wound Therapy in Diabetic Foot Ulcer.pptx
Negative Pressure Wound Therapy in Diabetic Foot Ulcer.pptxNegative Pressure Wound Therapy in Diabetic Foot Ulcer.pptx
Negative Pressure Wound Therapy in Diabetic Foot Ulcer.pptx
 
Mgr university bsc nursing adult health previous question paper with answers
Mgr university  bsc nursing adult health previous question paper with answersMgr university  bsc nursing adult health previous question paper with answers
Mgr university bsc nursing adult health previous question paper with answers
 
Top 10 Most Beautiful Chinese Pornstars List 2024
Top 10 Most Beautiful Chinese Pornstars List 2024Top 10 Most Beautiful Chinese Pornstars List 2024
Top 10 Most Beautiful Chinese Pornstars List 2024
 
Renal Replacement Therapy in Acute Kidney Injury -time modality -Dr Ayman Se...
Renal Replacement Therapy in Acute Kidney Injury -time  modality -Dr Ayman Se...Renal Replacement Therapy in Acute Kidney Injury -time  modality -Dr Ayman Se...
Renal Replacement Therapy in Acute Kidney Injury -time modality -Dr Ayman Se...
 
Unlocking Holistic Wellness: Addressing Depression, Mental Well-Being, and St...
Unlocking Holistic Wellness: Addressing Depression, Mental Well-Being, and St...Unlocking Holistic Wellness: Addressing Depression, Mental Well-Being, and St...
Unlocking Holistic Wellness: Addressing Depression, Mental Well-Being, and St...
 
JOURNAL CLUB PRESENTATION TEMPLATE DOCUMENT
JOURNAL CLUB PRESENTATION TEMPLATE DOCUMENTJOURNAL CLUB PRESENTATION TEMPLATE DOCUMENT
JOURNAL CLUB PRESENTATION TEMPLATE DOCUMENT
 
Unveiling Alcohol Withdrawal Syndrome: exploring it's hidden depths
Unveiling Alcohol Withdrawal Syndrome: exploring it's hidden depthsUnveiling Alcohol Withdrawal Syndrome: exploring it's hidden depths
Unveiling Alcohol Withdrawal Syndrome: exploring it's hidden depths
 

Ht Nlecture2009

  • 1. HTN new Updates Dr Ihab Suliman MBBS,ECFMG(USA),DCBNC(USA), MRCP(UK) Associate Consultant Cardiology Member of the European Working Group on Nuclear Cardiology & Cardiac CT
  • 2.
  • 3.
  • 4.
  • 5.
  • 6.
  • 7.
  • 8.
  • 9.
  • 10.
  • 11.
  • 12.
  • 13.
  • 14.
  • 15.
  • 16.
  • 17.
  • 18.
  • 19.
  • 20.
  • 21. Algorithm for Treatment of Hypertension (JNC 7) JAMA, May 2003 Not at Goal Blood Pressure (<140/90 mmHg) (<130/80 mmHg for those with diabetes or chronic kidney disease) Initial Drug Choices Lifestyle Modifications Drug(s) for the compelling indications With Compelling Indications Stage 2 Hypertension 2-drug combination for most Stage 1 Hypertension Thiazide-type diuretics for most. May consider ACEI, ARB, BB, CCB, or combination Without Compelling Indications
  • 22.
  • 23.
  • 24.
  • 25.
  • 26.
  • 27.
  • 28.
  • 29.
  • 30.
  • 31.
  • 32.
  • 33.
  • 34.
  • 35.
  • 36.
  • 37.
  • 38.
  • 39.
  • 40.
  • 41.
  • 42.
  • 43.
  • 44.
  • 45. Development of new diabetes – CHARM study 0 10 20 30 40 50 60 70 80 No. of cases developing new Diabetes Control candesartan 40% p =0.005 Lancet, 2003
  • 46.
  • 47.